Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2020 08:00 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Announces Change in Leadership

NEW YORK, March 27, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease...
March 17, 2020 08:03 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Announces Publication Analyzing Biomarkers of Synapse Damage or Loss to Support Future Therapeutic Development Efforts in Alzheimer's Disease

New York, March 17, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease...
November 20, 2019 08:03 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics to Give Webcast Presentation at Annual Piper Jaffray Healthcare Conference on December 3, 2019

PITTSBURGH, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
November 04, 2019 08:02 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Expands Leadership Team with Appointment of James M. O’Brien as Chief Financial Officer

PITTSBURGH, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
October 15, 2019 08:03 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Sponsoring Satellite Symposium on “Sigma-2 Receptors: Role in Health and Disease” during Society for Neuroscience Annual Meeting

PITTSBURGH, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
October 10, 2019 08:02 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics to Present Findings from the Elayta™ Clinical Development Program at Society for Neuroscience Annual Meeting

Pittsburgh, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
September 10, 2019 08:16 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics’ Founder/CSO to Provide Update on Elayta™ Clinical Progress at ADDF Alzheimer’s Drug Discovery Conference

Pittsburgh, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
September 04, 2019 08:04 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics to Give Webcast Presentation at 3rd Annual Janney Healthcare Conference on September 9, 2019

Pittsburgh, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
July 24, 2019 09:27 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Extends IP Coverage of Alzheimer’s Therapeutic Elayta™ to Additional Major Pharmaceutical Markets with Patent Issuances in Japan and China

Pittsburgh, July 24, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
July 09, 2019 08:02 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Receives $3.3 Million NIA Grant to Conduct qEEG Study of Elayta™ with World-Leading Alzheimer’s Biomarker Experts

PITTSBURGH, July 09, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...